Introduction
The authors provide a good overview, but should in my opinion include a brief statement on the on-going COLOFOL study, which have randomized several thousands of patients, and allocated patients to more or less radiological surveillance.
Methods
Exclusion criteria include "7) They are missing important information necessary for the conduct of the study (e.g. disease stage)."
This might introduce bias, as these excluded patients (especially if they are numerous) are probably not missing completely at random, but are representing a selection process. I would suggest that these patients are indeed kept in the study, but investigated within a multiple imputation framework and/or sensitivity analysis setting.
Statistical section
This section needs to be expanded, to allow the interested reader the possibility to judge the soundness of the planned comparison. For instance, there is no mention of handling of missing data (complete case, imputation?), or what covariates are supposed to be entered into the regression models, including the propensity score. I would also recommend a clearer (list or table) presentation of primary and secondary outcomes, and in what order results are to be presented. Any sensitivity analyses should also be specified beforehand.
Moreover, the reader should also be informed how the covariates are to be selected. If I read correctly, the following is the only information pertaining to this: "In constructing the appropriate comparison groups, the survival models above will be stratified according to tumor typography (colon/rectum), surveillance guidelines, and treatment received. For example, as the surveillance guidelines are the same, we will combine colon cancer patients with stage II/III disease who received both surgery and adjuvant chemotherapy as treatment. "
Proper modeling might include age, sex, other demographics, structural differences (geography, hospital type) etc, and I suppose the authors are going to take such factors into account; this should therefore be stated explicitly. The covariate selection should also be motivated by the researchers, either by use of literature alone or by for instance the construction of causal diagrams, elucidating the pathways from adherence to outcomes and thus allowing the reader and the researcher to discern true confounders, mediators and redundant covariates.
In conclusion, the study protocol and the subsequent study is a commendable effort to provide real-world data to this important issue. The authors have done a great job to describe the beautiful registry-based methodology in deriving a pertinent sub cohort of patients, thus emulating a trial situation in part. However, particularly the statistical section needs to be expanded to a great degree along the lines above. Please leave your comments for the authors below This is a protocol for an observational study on the effectiveness of surveillance after colorectal cancer surgery, using administrative data in the US. I have some comments, as stated below:
VERSION 1 -AUTHOR RESPONSE
Article summary:
1. Should include as a weakness (may be phrased better obviously): a) Validity of the registry data may not be optimal and could introduce bias The National Cancer Institute's SEER program is a national cancer registry made up of diverse (geographically and demographically) population-based cancer registries across the United States. The cancer registries included in the SEER program represent approximately 28% of the US population and are meant be representative of the entire US population. The registries that comprise the SEER program are known for the highest quality of cancer data reporting. As noted by Warren et al: 1 The SEER data are considered highly valid. All of the SEER registries hold the highest level of certification of data quality as provided by the North American Association of Central Cancer Registries.2 Every year, studies are conducted in the SEER areas to evaluate the quality and completeness of the data being reported. The SEER program's standard for the completeness of case ascertainment is 98%. In addition, each year the SEER registries reabstract medical records for a sample of cases to evaluate the accuracy of each of the data elements collected from the records.
As it has been shown that the SEER data are highly valid, we do not feel that this is a threat to validity and thus, not a limitation of our study.
b) The selection process with Medicare renders the study far from population-based and therefore introduces inevitable selection bias Medicare is a federal insurance program in the US that provides health insurance to adults ≥ 65 years of age and younger people with certain disabilities. Ninety-seven percent of all individuals ≥ 65 years of age receive primary health insurance coverage via Medicare.1 Thus, the Medicare population that is ≥ 65 years is almost identical to the entire 65 years and older US population. However, yes, this is an older population. Thus, the relationship between receipt of cancer surveillance testing and survival in older patients may not be entirely representative of the this relationship for those < 65 years of age. We have noted this as a limitation. Introduction
The authors provide a good overview, but should in my opinion include a brief statement on the ongoing COLOFOL study, which have randomized several thousands of patients, and allocated patients to more or less radiological surveillance. We have included the COLOFOL trial in our Introduction.
Methods
This might introduce bias, as these excluded patients (especially if they are numerous) are probably not missing completely at random, but are representing a selection process. I would suggest that these patients are indeed kept in the study, but investigated within a multiple imputation framework and/or sensitivity analysis setting. We have removed this exclusion and included a paragraph in our statistical analysis section describing our procedure for handling missing values and conducting a sensitivity analysis.
Statistical section
This section needs to be expanded, to allow the interested reader the possibility to judge the soundness of the planned comparison. For instance, there is no mention of handling of missing data (complete case, imputation?), or what covariates are supposed to be entered into the regression models, including the propensity score. I would also recommend a clearer (list or table) presentation of primary and secondary outcomes, and in what order results are to be presented. Any sensitivity analyses should also be specified beforehand. As requested, this section has been greatly expanded in an effort to provide greater clarity to our process. The primary and secondary exposure-outcome relationships have been added to the manuscript. We have chosen to present the order of results as: 1) bivariate analysis of patients' sociodemographic and clinical characteristics according to levels of surveillance, 2) Binomial regression results displaying the association between patients' characteristics and receipt of adherent/mostly adherent surveillance testing, and 3) results of the survival analysis displaying hazard ratios for levels of surveillance associated with survival. That is, we are building up to the most important results for our study. As such, we've ordered our description of the statistical analysis to correspond to the order in which results will be presented. Moreover, the reader should also be informed how the covariates are to be selected. If I read correctly, the following is the only information pertaining to this: "In constructing the appropriate comparison groups, the survival models above will be stratified according to tumor typography (colon/rectum), surveillance guidelines, and treatment received. For example, as the surveillance guidelines are the same, we will combine colon cancer patients with stage II/III disease who received both surgery and adjuvant chemotherapy as treatment. "
Proper modeling might include age, sex, other demographics, structural differences (geography, hospital type) etc, and I suppose the authors are going to take such factors into account; this should therefore be stated explicitly. The covariate selection should also be motivated by the researchers, either by use of literature alone or by for instance the construction of causal diagrams, elucidating the pathways from adherence to outcomes and thus allowing the reader and the researcher to discern true confounders, mediators and redundant covariates. We thank the reviewers for their comments. As requested, this section has been expanded in an effort to provide greater clarity to our process.
In conclusion, the study protocol and the subsequent study is a commendable effort to provide realworld data to this important issue. The authors have done a great job to describe the beautiful registry-based methodology in deriving a pertinent sub cohort of patients, thus emulating a trial situation in part. However, particularly the statistical section needs to be expanded to a great degree along the lines above.
Thank you. In this revision, we hope to have addressed your concerns by providing greater explanation and clarity in describing our approach.
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